A Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
Phase I Clinical Study to Evaluate the Tolerability and Pharmacokinetics of TQB3617 Capsule in Patients With Advanced Malignant Tumors
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A PHASE1 clinical study on Advanced Malignant Tumors, this trial is ongoing. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE1
Status: Unknown Status → Unknown
-
Mar 2024 — Jul 2024 [monthly]
Unknown Status PHASE1
Status: Recruiting → Unknown Status
-
Mar 2022 — Mar 2024 [monthly]
Recruiting PHASE1
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Dec 2021 — Feb 2022 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .